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Seventeen years of drug-resistant tuberculosis
in Argentinian children
G. Berberian ∗, S. Gonzalez, V. Reijtman, N. Min˜o,
L. Casimir, C. Sarkis, D. Mecicovsky, M.T. Rosanova
Hospital de Pediatria JP Garrahan, Buenos Aires,
Argentina
Background: The emergence of strains of Mycobacterium tuber-
culosis (Mt) that are resistant to antimycobacterial agents (DR-TB)
is a worldwide problem of which the magnitude has not been well
described specially in pediatric patients. TB susceptibility surveil-
lance and risk factors for DR-TB are important issues to consider
at the moment of pediatric TB treatment. OBJECTIVE: To asses the
prevalence of DR- TB in children, and identify clinical features, risk
factors, and outcome of pediatric patients with DR-TB.
Methods & Materials: Retrospective review of all mycobac-
terial samples send to microbiological evaluation from 1998 to
2015 at Hospital PediatríaGarrahan. We analyzed 46 patients (p),
with microbiological conﬁrmation of DR-TB. Resistance tests to
ﬁrst line drugs: Isoniazid (INH), Rifampicin (RMP) Pyrazinamide
(PZ), Ethambutol (EMB), Streptomycin (STO) were performed on
Lowenstein- Jensen medium and BACTEC 460 TB system. We
deﬁned DR-TB at those strains of Mt resistant to one or more ﬁrst-
line drugs. We divided into single or resistant to 2 or more drugs.
In the latter group, we recorded the data in two mutually exclusive
categories: multidrug resistant TB strains (MDR-TB, those resistant
to at least INH+RMP), and resistant to 2 or more drugs (other than
INH+RMP)
Results: We included 1195 TB p, 478 bacteriologically positive
conﬁrmed culture. Forty six strains (9.6%) were DR-TB. Primary
resistance was found in 39/46 (85%). The median age was 130
months (r: 2-204),16 (35%) were immunocompromised, 75% of
whom HIV positive. Pulmonary disease was the most common
presentation: 29 p (60%). Eighteen p (40%) had extra-pulmonary
localization. Of 46 DR-TB cultures 28 (60%) were monorresistant
and 18 (40%) resistant to 2 o more drugs. Ten were MDR-TB 8 of
who hadHIV infection.Monorresistance for INH, RMP, PZ, EMB and
STO were 1.6% 0.2%, 0%, 0.2% and 4% respectively. Resistance to
INH was 3%. Fourteen p (30%) had TB contact, 9 (19%) had previ-
ous hospital admission, and 7 (15%) previous TB treatment. Three
p (6%) died because of TB, all of them with central nervous system
infection.
Conclusion: DR-TB is infrequent in pediatric patients. MR-TB is
associatedwithHIV. INH resistancewas present in 3% of all isolated
strains.
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Early cardiac safety of the 9-11 month Short
course regimen for MDR-TB treatment
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Background: Only 48% of multidrug resistant tuberculo-
sis (MDR-TB) patients worldwide receive successful outcomes.
Shorter, more effective regimens are required. The cardiac safety of
the 9-11 month “Bangladesh regimen” has been largely unstudied.
The regimenwaspiloted inUzbekistan andasperWHOrecommen-
dations, electrocardiographic (ECG) monitoring was performed in
the early phase of treatment. We aim, in this interim analysis, to
describe the early cardiac safety of this regimen.
Methods & Materials: Consecutively diagnosed MDR patients
were recruited from Karakalpakstan, Uzbekistan. Moxiﬂoxacin
400mg and clofazimine 100mg daily were included in the regi-
men. Patients had a single, 12 lead ECG performed at baseline, 2
and 4 weeks of therapy. RR and QT interval length was measured
using lead II or V2 on the ECG printouts. QT was corrected using
Fridericia’s formula (QTcF). Data was prospectively collected using
a standardised database (Koch 6, MSF, Paris) and analysed using
openEpi (Ver 3.03, accessed 26/7/2015).
Results: Between September 2013 and March 2015, 146
patients were enrolled. No patients were excluded from the study
due to baseline cardiac ﬁndings or QT prolongation. Of these, 121
had ECGs performed per protocol and available for analysis. 27
(22.3%) were over 50 years of age and six had a reported history
of cardiac disease. 12 patients (9.9%) had increases >60 ms from
baseline with 1 patient showing an increase at both time points.
Only one of these patients had QTcF increased over 450 ms. No
patients hadQTcF >500msduring the screening period. Nopatients
reported syncope or seizures and there were no deaths during the
screening period. Univariate analysis of those with QT prolonga-
tion versus no QT prolongation did not identify other signiﬁcant
risk factors.
Table 1 - ECG data
